70% is not good enough.
Current testing methodologies, including qPCR, are only 60%-80% accurate.
qPCR Sensitivity Issues are Not Limited to SARS-CoV-2 Diagnostics
“We show that current methods for real-time PCR assay design have unacceptably low sensitivities for most clinical applications.”
-Lemmon (2008)
Bacterial pathogens: 48.8% (Roche Septifast)
Respiratory virus panel: 84.5% (BioFire FilmArray)
Pulmonary/extrapulmonary TB: 72-82% (meta-analysis)
Neurosyphilis: 40-70% (meta-analysis)
Single-strand RNA viruses: 70%
ANDE® Biosurveillance and HMAC: Addressing an Existential Risk
ANDE® Biosurveillance technology - HMAC - represents a generational leap to both protect against bioweapons and prevent future pandemics.
Benefits:
HMAC assays are essentially focused sequencing - generating the most important, actionable genomic information quickly, in less than two hours.
HMAC is commercially proven.
HMAC assays simultaneously interrogate dozens of pathogens and dozens of genomic sites per pathogen - all in a single test.
HMAC is much more accurate than qPCR, sequencing, and other conventional approaches.
HMAC - unlike conventional approaches - is highly resistant to assay destruction by mutations.
HMAC enables contact tracing, virulence determination, forensic attribution, potential treatment regimens, and deployment of specific countermeasures all become possible - in real time.
The HMAC system was built to work outside the lab - by non-technical operators at farms, food processing plants, transport check stations, office buildings, police stations, clinics and physician’s offices, borders and ports, the battlefield - essentially anywhere, anytime.
ANDE® Rapid HMAC for Biosurveillance
Approaches 100% accuracy - with greater sensitivity than other options.